Skip to content
Open access

Population Pharmacokinetics and Detection Times of Betamethasone After Intravenous, Intramuscular, and Intranasal Jet Administration of Betamethasone Sodium Phosphate in Horses.

Sep 2026 · Drug Testing and Analysis · 0 citations · 19 references
Medicine

TL;DR

The applicability of the estimated DTs should be interpreted according to the regulatory framework governing the use of human BETP formulations and their routes of administration in the relevant jurisdiction.

Abstract

Betamethasone sodium phosphate (BETP) is a glucocorticosteroid used in humans. The primary objective was to estimate irrelevant plasma (IPC) and urine (IUC) concentrations using a pharmacokinetic/pharmacodynamic approach based on systemic clearance estimated from intravenous (IV) pharmacokinetic data. As a secondary objective, detection times (DTs) following IV, intramuscular (IM), and intranasal jet (INJ) administration were estimated for medication control. Plasma and urine concentrations were obtained from a total of 20 horses in Japan and Germany, with some horses contributing to more than one route after single IV (0.06 mg/kg, n = 7; 0.04 mg/kg, n = 8), single IM (20 mg/horse, n = 7), and multiple INJ (4 mg/horse for 5 days, n = 6) administration. The data were analyzed using a nonlinear mixed-effects model. The plasma clearance was 276 mL/kg/h, and the steady-state urine-to-plasma ratio was 25.8. For IV administration at 0.06 and 0.04 mg/kg every 24 h, the IPCs were 0.018 and 0.012 ng/mL, and the corresponding IUCs were 0.47 and 0.31 ng/mL, with the latter IUC close to the current International Federation of Horseracing Authorities international screening limit (ISL) (0.2 ng/mL). All horses fell below the ISL within 72 h after single IV administration at 0.06 and 0.04 mg/kg and after single IM administration, whereas all horses fell below the ISL within 48 h after INJ administration. The applicability of the estimated DTs should be interpreted according to the regulatory framework governing the use of human BETP formulations and their routes of administration in the relevant jurisdiction.

Read PDF

Similar papers

Open access Oct 2026

Pharmacokinetics of tramadol and O-desmethyltramadol in healthy dogs after a single oral dose of 2 mg/kg.

Tramadol exposure after low oral doses is variable in dogs, and the estimation of the terminal phase can be difficult when late concentrations plateau or rebound. This study characterized tramadol and O-desmethyltramadol (M1) after a single oral dose of 2 mg/kg in 10 healthy female mixed-breed dogs. Plasma was collecte...

Yanna D. B. Passos, N. Fernandes, K. Arcoverde et al. · 0 citations
Open access Oct 2026

The pharmacokinetics of a single intravenous dose of difelikefalin in adolescents aged 12 to 17 years on hemodialysis.

BACKGROUND The aim of this study was to evaluate the pharmacokinetic profile, safety, and tolerability of a single intravenous bolus injection of difelikefalin in adolescents on maintenance hemodialysis. METHODS In this multicenter, open-label study, adolescents (12 to 17 years old) received a single difelikefalin do...

C. Mourani, Amrit Kaur, Pauline Abou Jaoudeh et al. · 0 citations
Open access Sep 2026

Pharmacokinetics of Buccally Administered Cannabidiol and Oral Carprofen During Single- and Repeated-Dose Administration in Dogs.

Repeated dosing resulted in increasing 2-h post-dose CBD concentrations over time, and 7-COOH-CBD showed greater exposure and persistence than 7-OH-CBD, while carprofen pharmacokinetics were consistent with previous reports.

T. Vake, K. Tomsič, Žiga Žgank et al. · 0 citations
Open access Sep 2026

Prior-informed population pharmacokinetic-pharmacodynamic modeling of dexamethasone in horses

Dexamethasone (DEX) is widely used in equine practice with diverse studies having characterized its pharmacokinetics (PK) and pharmacodynamics (PD) including our published comprehensive meta-analysis. Individual DEX concentrations in plasma and urine and serum cortisol from five studies (n = 32 horses) were analyzed us...

Rui-Hong Yu, P. Toutain, C. Ekstrand et al. · 0 citations
Open access Oct 2026

Absorption, distribution, metabolism and excretion of londamocitinib after single-dose inhaled, intravenous and oral administration in healthy participants.

AIM Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open-label, two-part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption, distribution, metabolism and excretion (...

C. Riff, Peter Bold, M. Heijer et al. · 0 citations
Open access Oct 2026

Population pharmacokinetic/pharmacodynamic modeling of linezolid in critically ill adult patients

Objective. To evaluate pharmacokinetics using therapeutic drug monitoring (TDM) data and develop a population pharmacokinetic/pharmacodynamic (PK/PD) model of linezolid for individualizing dosage regimens in critically ill adult patients in intensive care unit (ICU). Materials and Methods. A retrospective study of lin...

I. Bondareva, S. Zyryanov, M. S. Chenkurov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.